Direction at a glance
Injectable and extended-duration antiretroviral platforms aim to reduce dosing burden while maintaining suppression. Current research explores wider populations, longer intervals, oral weekly regimens and combinations with new mechanisms.
What the evidence establishes
- WHO's 2026 recommendations include long-acting injectable therapy in selected circumstances.
- Long-acting regimens still require complete combination activity and resistance-aware clinical selection.
- Implementation depends on reliable appointment, pharmacy and cold-chain systems.
Next decisive research questions
Limits and responsible interpretation
What this direction does not yet prove
No long-acting regimen is suitable for every person or resistance profile. Missed-dose management and access infrastructure remain material constraints.
Development pathway
| Decision | Required evidence |
|---|---|
| Biological activity | Target engagement and an outcome that cannot be explained by assay noise or selection. |
| Clinical value | Meaningful benefit, adequate follow-up, safety, comparison with current standard care and transparent uncertainty. |
| Generalizability | Diverse populations, subtypes, geographies, ages and clinically relevant comorbidities. |
| Scalability | Manufacturing, delivery, monitoring, price, workforce and community acceptability. |
Principal sources and evidence gateways
Links checked 18 August 202601
WHO updated recommendations on HIV clinical managementWorld Health Organization · Guideline · Access checked 18 Aug 2026
↗02Clinical guidelines for HIV prevention and treatmentNIH Clinicalinfo · Guideline · Access checked 18 Aug 2026
↗03ClinicalTrials.gov HIV study registryU.S. National Library of Medicine · Registry · Access checked 18 Aug 2026
↗